ELEV Elevation Oncology, Inc.

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

$1.51
As of 06/24/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/22/2012
Outstanding shares:  23,253,966
Average volume:  405,201
Market cap:   $34,648,409
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.28
PS ratio:   0.00
Return on equity:   -53.80%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy